CSF2 and COVID-19: Furthermore, pacritinib suppresses Th1 cells that initiate cytokine release syndrome (CRS) pathogenesis through GM-CSF (pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe patients with COVID-19).